Verrica Pharmaceuticals Stock Forecast, Price & News

Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

Is Verrica Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verrica Pharmaceuticals stock.
View analyst ratings for Verrica Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Verrica Pharmaceuticals?

Wall Street analysts have given Verrica Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Verrica Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Verrica Pharmaceuticals?

Verrica Pharmaceuticals saw a drop in short interest in September. As of September 30th, there was short interest totaling 1,480,000 shares, a drop of 21.3% from the September 15th total of 1,880,000 shares. Based on an average daily trading volume, of 122,100 shares, the short-interest ratio is presently 12.1 days. Currently, 11.2% of the company's stock are short sold.
View Verrica Pharmaceuticals' Short Interest.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Verrica Pharmaceuticals.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its earnings results on Tuesday, August, 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.02.
View Verrica Pharmaceuticals' earnings history.

How has Verrica Pharmaceuticals' stock been impacted by Coronavirus?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VRCA stock has increased by 21.4% and is now trading at $12.77.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for VRCA?

5 brokers have issued 12 month price targets for Verrica Pharmaceuticals' shares. Their forecasts range from $16.00 to $20.00. On average, they expect Verrica Pharmaceuticals' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 48.8% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:

• Ted White, President, Chief Executive Officer & Director
• Terry Kohler, Chief Financial & Accounting Officer
• Gary Goldenberg, Chief Medical Officer
• Eugene Scavola, Executive Vice President-Technical Operations
• Christopher G. Hayes, Secretary, Chief Legal & Compliance Officer

Who are some of Verrica Pharmaceuticals' key competitors?

Some companies that are related to Verrica Pharmaceuticals include Bicycle Therapeutics (BCYC), Vectura Group (VEGPF), PureTech Health (PRTC), Organogenesis (ORGO), uniQure (QURE), Madrigal Pharmaceuticals (MDGL), Xenon Pharmaceuticals (XENE), Nurix Therapeutics (NRIX), Generation Bio (GBIO), ImmunoGen (IMGN), Arcturus Therapeutics (ARCT), MacroGenics (MGNX), Kura Oncology (KURA), MannKind (MNKD) and DICE Therapeutics (DICE).
View all of VRCA's competitors.

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI) and Aeterna Zentaris (AEZS).

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $12.77.

How much money does Verrica Pharmaceuticals make?

Verrica Pharmaceuticals has a market capitalization of $351.37 million. The company earns $-42.69 million in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Verrica Pharmaceuticals have?

Verrica Pharmaceuticals employs 29 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

Where are Verrica Pharmaceuticals' headquarters?

Verrica Pharmaceuticals is headquartered at 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at (434) 453-3300 or via email at [email protected].